Objective To observe efficacy and safety of docetaxel plus capecitabine as second -line treatment in treating patients with advanced non-small cell lung cancer (NSCLC). Methods 26 patients who failed in platinum - based first-line chemotherapy with good performance status (scoring 0-1) were treated with docetaxel plus capecitabine. The objective curative effect, survival time and adverse reactions were evaluated. Results Among the 26 patients, there were 5 cases of PR, 10 cases of SD, 11 cases of PD. The median progression-free survival time was 5.2 months, the median overall survival time was 9. 6 months, and the 1-year survival rate was 26. 92% . 5 cases had grade HI ~IV neutropenia, only 1 case had grade HI hand-foot syndrome. Conclusion Combination of docetaxel and capecitabine as second-line treatment is an effective chemotherapy regimen for patients with advanced noirsmall cell lung cancer,and its side effects also can be tolerated.%目的 观察多西他赛联合卡培他滨在晚期非小细胞肺癌(NSCLC)二线治疗中的疗效及安全性.方法 本院26例以铂类为主的晚期NSCLC患者一线化疗失败后,对PS i平分较好(0～1分)的患者给予多西他赛+希罗达联合化疗.评价客观疗效、生存时间及不良反应.结果 26例患者中,未见完全缓解(CR)患者,部分缓解(PR)5例,疾病稳定(SD)10例,疾病进展(PD)11例.中位无进展生存时间5.2个月,中位总生存时间9.6个月,1年生存率26.92％.5例出现Ⅲ～Ⅳ度中性粒细胞下降,1例出现Ⅲ度手足综合征.结论 多西他赛联合卡培他滨在晚期NSCLC的二线治疗中是一个有效的化疗方案,毒副反应可以耐受.
展开▼
